Kari Neemann
Pediatric Infectious Diseases Omaha, NE Medical Doctor
NPI 1699989442 CMS profile 1123588
8200 Dodge St, Omaha, NE 68114
General payments
$117
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$26,017
Through program year 2025, Kari Neemann of Omaha, NE is reported in the CMS Open Payments database as having received $117 across 1 general payment and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $26,017 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 35th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $117 | 1 |
Beside peers
- Kari Neemann
- Pediatric Infectious Diseases median
- Middle half of Pediatric Infectious Diseases
- National median
In program year 2025, general payments to Kari Neemann were reported at $117. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.
Show as a table
| Year | Kari Neemann | Pediatric Infectious Diseases median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $175 | $34–$2,175 | $163 |
| 2020 | $0 | $521 | $34–$6,009 | $114 |
| 2021 | $0 | $1,077 | $39–$4,557 | $132 |
| 2022 | $0 | $232 | $53–$6,196 | $149 |
| 2023 | $0 | $140 | $52–$4,662 | $160 |
| 2024 | $0 | $198 | $52–$3,860 | $164 |
| 2025 | $117 | $126 | $41–$2,094 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
11
Drug cost
$287
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cefazolin Sodium | Generic | 11 | $287 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 3 billing codesPaid by Medicare
$4,839
Medicare patients
17
Services billed
57
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Infectious Diseases in Nebraska
Related records
Pediatric Infectious Diseases in Nebraska
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Infectious Diseases
Everyone recorded under this specialty, nationwide.
Doctors in Nebraska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.